OBJECTIVE: To evaluate the efficacy of topoisomerase I inhibitor, topotecan, in patients with recurrent BRCA+ versus BRCA- ovarian, fallopian tube, and primary peritoneal carcinomas. METHODS: A single-institution retrospective analysis of platinum-resistant patients characterized for the presence or absence of known deleterious BRCA mutations. Patients received topotecan at a dose and schedule determined by their treating physician (five day or weekly). Response rate and progression-free survival (PFS) were assessed. RESULTS: A total of 50 patients (9 BRCA+, 41 BRCA-) were treated with topotecan. Both groups were well balanced in terms of age, stage, grade, and number of prior therapies. All patients had high-grade serous carcinoma. The clinical benefit rate in BRCA+ and BRCA- patients was 0% and 26.8% (6 PRs, 6 SDs), respectively (p=0.18). Median PFS in BRCA+ and BRCA- pts was 1.7 months (95% CI: 1.0-2.8 months) and 2.5 months (95%CI: 1.9-2.8 months), respectively (p=0.057). Median time to best response was 1.9 months, and median response duration 2.6 months. CONCLUSIONS: This analysis in a heavily pretreated cohort of patients fails to support the superiority of topotecan in BRCA+ platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. Further study of this class of agents, specifically in less heavily-pretreated patients, may still be warranted.
OBJECTIVE: To evaluate the efficacy of topoisomerase I inhibitor, topotecan, in patients with recurrent BRCA+ versus BRCA- ovarian, fallopian tube, and primary peritoneal carcinomas. METHODS: A single-institution retrospective analysis of platinum-resistant patients characterized for the presence or absence of known deleterious BRCA mutations. Patients received topotecan at a dose and schedule determined by their treating physician (five day or weekly). Response rate and progression-free survival (PFS) were assessed. RESULTS: A total of 50 patients (9 BRCA+, 41 BRCA-) were treated with topotecan. Both groups were well balanced in terms of age, stage, grade, and number of prior therapies. All patients had high-grade serous carcinoma. The clinical benefit rate in BRCA+ and BRCA- patients was 0% and 26.8% (6 PRs, 6 SDs), respectively (p=0.18). Median PFS in BRCA+ and BRCA- pts was 1.7 months (95% CI: 1.0-2.8 months) and 2.5 months (95%CI: 1.9-2.8 months), respectively (p=0.057). Median time to best response was 1.9 months, and median response duration 2.6 months. CONCLUSIONS: This analysis in a heavily pretreated cohort of patients fails to support the superiority of topotecan in BRCA+platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. Further study of this class of agents, specifically in less heavily-pretreated patients, may still be warranted.
Authors: Gordon J S Rustin; Michael Quinn; Tate Thigpen; Andreas du Bois; Eric Pujade-Lauraine; Anders Jakobsen; Elizabeth Eisenhauer; Satoru Sagae; Kathryn Greven; Ignace Vergote; Andres Cervantes; Jan Vermorken Journal: J Natl Cancer Inst Date: 2004-03-17 Impact factor: 13.506
Authors: Y Ben David; A Chetrit; G Hirsh-Yechezkel; E Friedman; B D Beck; U Beller; G Ben-Baruch; A Fishman; H Levavi; F Lubin; J Menczer; B Piura; J P Struewing; B Modan Journal: J Clin Oncol Date: 2002-01-15 Impact factor: 44.544
Authors: D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman Journal: Am J Hum Genet Date: 1998-03 Impact factor: 11.025
Authors: D J Gallagher; J A Konner; K M Bell-McGuinn; J Bhatia; P Sabbatini; C A Aghajanian; K Offit; R R Barakat; D R Spriggs; N D Kauff Journal: Ann Oncol Date: 2010-11-17 Impact factor: 32.976
Authors: Noah D Kauff; Jaya M Satagopan; Mark E Robson; Lauren Scheuer; Martee Hensley; Clifford A Hudis; Nathan A Ellis; Jeff Boyd; Patrick I Borgen; Richard R Barakat; Larry Norton; Mercedes Castiel; Khedoudja Nafa; Kenneth Offit Journal: N Engl J Med Date: 2002-05-20 Impact factor: 91.245
Authors: Timothy R Rebbeck; Henry T Lynch; Susan L Neuhausen; Steven A Narod; Laura Van't Veer; Judy E Garber; Gareth Evans; Claudine Isaacs; Mary B Daly; Ellen Matloff; Olufunmilayo I Olopade; Barbara L Weber Journal: N Engl J Med Date: 2002-05-20 Impact factor: 91.245
Authors: H A Risch; J R McLaughlin; D E Cole; B Rosen; L Bradley; E Kwan; E Jack; D J Vesprini; G Kuperstein; J L Abrahamson; I Fan; B Wong; S A Narod Journal: Am J Hum Genet Date: 2001-02-15 Impact factor: 11.025
Authors: Marcia S Brose; Timothy R Rebbeck; Kathleen A Calzone; Jill E Stopfer; Katherine L Nathanson; Barbara L Weber Journal: J Natl Cancer Inst Date: 2002-09-18 Impact factor: 13.506
Authors: Hannah Farmer; Nuala McCabe; Christopher J Lord; Andrew N J Tutt; Damian A Johnson; Tobias B Richardson; Manuela Santarosa; Krystyna J Dillon; Ian Hickson; Charlotte Knights; Niall M B Martin; Stephen P Jackson; Graeme C M Smith; Alan Ashworth Journal: Nature Date: 2005-04-14 Impact factor: 69.504